Market Research Report
Autosomal Dominant Polycystic Kidney DiseasePipeline Insight, 2019
|Published by||DelveInsight Business Research LLP||Product code||910654|
|Published||Content info||60 Pages
Delivery time: 1-2 business days
|Autosomal Dominant Polycystic Kidney DiseasePipeline Insight, 2019|
|Published: September 1, 2019||Content info: 60 Pages||
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
" Autosomal Dominant Polycystic Kidney Disease (ADPKD) - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autosomal Dominant Polycystic Kidney Disease pipeline landscape is provided which includes the disease overview and Autosomal Dominant Polycystic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Autosomal Dominant Polycystic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autosomal Dominant Polycystic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
"Autosomal dominant polycystic kidney disease (ADPKD) is a genetic disorder characterized by the growth of numerous cysts in the kidneys. It is the most common inherited disorder of the kidneys. Symptoms usually develop between the ages of 30 and 40, but they can begin earlier, even in childhood. The most common symptoms are pain in the back and the sides and headaches. Other symptoms include liver and pancreatic cysts, urinary tract infections, abnormal heart valves, high blood pressure, kidney stones, brain aneurysms, and diverticulosis. According to National Institute of Diabetes and Digestive and Kidney Diseases, Autosomal dominant means the patient can get the PKD gene mutation, or defect, from only one parent. Researchers have found two different gene mutations that cause ADPKD. Most people with ADPKD have defects in the PKD1 gene, and 1 out of 6 or 1 out of 7 people with ADPKD have a defective PKD2 gene.
The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Autosomal Dominant Polycystic Kidney Disease (ADPKD) targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Autosomal Dominant Polycystic Kidney Disease (ADPKD) pipeline report covers 7+ companies. Some of the key players include Palladio Biosciences (Lixivaptan), Kadmon Corporation (Tesevatinib) etc.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.
To be continued in the report…………………………